SARTORIUS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.26 USD | +0.02% |
|
-10.29% | -36.16% |
| 06-20 | SARTORIUS VORZUEGE : UBS remains Neutral | ZD |
| 06-20 | Sartorius stabilizes after previous day's price slide | DP |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 60.42 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -36.16% | 14.68B | - | ||
| -52.23% | 2.36B | C+ | ||
| +23.01% | 1.94B | - | ||
| -10.06% | 1.5B | - | ||
| +21.24% | 1.23B | B+ | ||
| -23.46% | 880M | - | ||
| +1.33% | 782M | - | ||
| -34.13% | 752M | - | C- | |
| +23.58% | 593M | C+ | ||
| -29.66% | 589M | B+ |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SRT3 Stock
- SOAGY Stock
- Ratings Sartorius AG
